Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety...

by Stephen Silberstein, Merle Diamond, Nada A. Hindiyeh, David M. Biondi, Roger Cady, Joe Hirman, Brent Allan, Susan Pederson, Barbara Schaeffler, Jeff Smith
Published 2020-10-01

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials

by Timothy R. Smith, Egilius L. H. Spierings, Roger Cady, Joe Hirman, Barbara Schaeffler, Vivienne Shen, Bjørn Sperling, Thomas Brevig, Mette Krog Josiassen, Elizabeth Brunner, Loan Honeywell, Lahar Mehta
Published 2021-03-01

Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials

by Timothy R. Smith, Egilius L. H. Spierings, Roger Cady, Joe Hirman, Barbara Schaeffler, Vivienne Shen, Bjørn Sperling, Thomas Brevig, Mette Krog Josiassen, Elizabeth Brunner, Loan Honeywell, Lahar Mehta
Published 2021-05-01